SRR33532779
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.510
- MYC_TARGETS_V1+0.500
- PANCREAS_BETA_CELLS+0.500
- E2F_TARGETS+0.440
- MYC_TARGETS_V2+0.440
- MTORC1_SIGNALING+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.370
- G2M_CHECKPOINT+0.370
- HEDGEHOG_SIGNALING+0.370
- GLYCOLYSIS+0.310
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.210
- BILE_ACID_METABOLISM-0.210
- ESTROGEN_RESPONSE_EARLY-0.170
- IL6_JAK_STAT3_SIGNALING-0.170
- ESTROGEN_RESPONSE_LATE-0.150
- CHOLESTEROL_HOMEOSTASIS-0.120
- HEME_METABOLISM-0.110
- INTERFERON_GAMMA_RESPONSE-0.110
- UV_RESPONSE_DN-0.100
- KRAS_SIGNALING_DN-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 1F4CD8D0-E2FD-45AA-8CE2-8C0488916778 | — | — | 0.777 |
| 2 | SRR1313137 | — | E | 0.771 |
| 3 | MDT-AP-1249 | Med | Medulloblastoma | 0.768 |
| 4 | BS_1D6PZNKN | Diffuse intrinsic pontine glioma | — | 0.766 |
| 5 | SRR12202482 | — | — | 0.765 |
| 6 | MNG296 | — | — | 0.763 |
| 7 | BS_23QW0BBA | high-grade glioma | — | 0.757 |
| 8 | 5E729BD1-654D-4334-A80F-3EDD472551B4 | — | — | 0.753 |
| 9 | SRR10900569 | — | — | 0.751 |
| 10 | SRR33532784 | — | A | 0.750 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.510 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.500 | Cobimetinib | — uncovered |
| E2F_TARGETS | 0.440 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.440 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.370 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.370 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.370 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.310 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.310 | Idelalisib | — uncovered |
| HYPOXIA | 0.270 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.260 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.260 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.160 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.150 | Inavolisib | — uncovered |
| COAGULATION | 0.130 | Binimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.130 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.080 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.080 | Inavolisib | — uncovered |